Clinical InvestigationAcute Ischemic Heart DiseaseImproved diagnostic and prognostic performance of a new high-sensitive troponin T assay in patients with acute coronary syndrome
Section snippets
Background
Myocardial infarction is an acute and life-threatening clinical manifestation of coronary artery disease and is the major cause of death in developed countries. Immediate diagnosis, risk stratification, and initiation of a specific therapy are of foremost importance to improve clinical outcome in patients presenting with symptoms suggestive for an acute coronary syndrome (ACS).1
The measurement of cardiac troponins (cTn) plays a central role for the diagnosis of acute myocardial infarction (AMI)
Patients
We analyzed data from 2 independent patient cohorts, the Bad Nauheim ACS registry and the Prognosis in Acute Coronary Syndromes (PACS) registry, with a total of 2,506 patients. Both cohorts were different, with the Bad Nauheim ACS registry comprising a high-risk cohort with confirmed ACS, and the PACS registry, a lower-risk chest pain cohort.12, 13 Accordingly, we analyzed both populations separately.
The Bad Nauheim ACS registry included consecutive patients (n = 1,023) from April 2003 until
Results
A total of 2,506 patients were analyzed, 1,023 from the Bad Nauheim ACS registry and 1,483 patients from the PACS registry.
Baseline data of both cohorts are depicted in Table I. Patient's characteristics regarding gender, age, and presence of conventional risk factors were similar in both groups. However, in the PACS cohort, the diagnosis of myocardial infarction was less frequent, as well as the finding of TnT (>30 pg/mL) or hsTnT (>14 pg/mL) elevation as compared with that in the Bad Nauheim
Discussion
The main findings of this study were, first, an improved diagnostic accuracy of TnT when measured with the hsTnT assay, specially in patients presenting early after the onset of symptoms; second, a high diagnostic accuracy of the high-sensitive troponin assay in patients who are troponin T negative with the contemporary assay; and third, an incremental prognostic value of the high-sensitive assay, allowing improved risk stratification also in patients with negative troponin T levels on
Conclusion
Troponin T measured with a newly developed high-sensitive troponin T assay provides better diagnostic information for the diagnosis of an AMI in patients with symptoms suggestive for an ACS, particularly, very early after the onset of symptoms. Furthermore, the prognostic information derived from the high-sensitive troponin testing is superior to the contemporary troponin test. The implementation of this new assay into clinical routine therefore allows earlier and improved decision making.
Disclosures
Michael Weber, Lecture fees by Roche Diagnostics and Abbott Diagnostics.
Oscar Bazzino, No disclosures.
Jose Luis Navarro Estrada, No disclosures.
Raul de Miguel, No disclosures.
Simon Salzberg, No disclosures.
Juan J. Fuselli, No disclosures.
Christoph Liebetrau, No disclosures.
Mariella Woelken, No disclosures.
Helge Moellmann, No disclosures.
Holger Nef, No disclosures.
Christian Hamm, Lecture fees by Roche Diagnostics and Abbott Diagnostics, Advisory Board Abbott Diagnostics.
Acknowledgements
The Bad Nauheim ACS registry was funded by a grant from the Kerckhoff-Stiftung, Bad Nauheim Germany. The PACS study was funded by a grant from Sanofi Aventis (Buenos Aires, Argentina). Roche Diagnostics (Mannheim, Germany) provided the assays for measurement of troponin T and high-sensitive troponin T free of charge. No other extramural funding was used to support this work.
References (18)
- et al.
Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM study investigators. Platelet receptor inhibition in ischemic syndrome management
Lancet
(1999) - et al.
ACC/AHA 2007 guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
J Am Coll Cardiol
(2007) - et al.
Universal definition of myocardial infarction
J Am Coll Cardiol
(2007) - et al.
N-terminal B-type natriuretic peptide assessment provides incremental prognostic information in patients with acute coronary syndromes and normal troponin t values upon admission
J Am Coll Cardiol
(2008) - et al.
Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I
J Am Coll Cardiol
(2010) - et al.
National hospital ambulatory medical care survey: 2005 emergency department summary
Adv Data
(2007) - et al.
Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I
N Engl J Med
(1997) - et al.
Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. C7e3 fab antiplatelet therapy in unstable refractory angina (capture) study investigators
N Engl J Med
(1999) - et al.
Guidelines for the diagnosis and treatment of non–ST-segment elevation acute coronary syndromes
Eur Heart J
(2007)
Cited by (0)
- e
Both authors contributed equally